000125525 001__ 125525
000125525 005__ 20240228143314.0
000125525 0247_ $$2doi$$a10.1182/blood-2015-10-676361
000125525 0247_ $$2pmid$$apmid:27257181
000125525 0247_ $$2ISSN$$a0006-4971
000125525 0247_ $$2ISSN$$a1528-0020
000125525 0247_ $$2altmetric$$aaltmetric:8449218
000125525 037__ $$aDKFZ-2017-01651
000125525 041__ $$aeng
000125525 082__ $$a610
000125525 1001_ $$0P:(DE-He78)c741dc7f974390ad4310349f29aac40b$$aBochtler, Tilmann$$b0$$eFirst author$$udkfz
000125525 245__ $$aPrognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study.
000125525 260__ $$aStanford, Calif.$$bHighWire Press$$c2016
000125525 3367_ $$2DRIVER$$aarticle
000125525 3367_ $$2DataCite$$aOutput Types/Journal article
000125525 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1524212023_3007
000125525 3367_ $$2BibTeX$$aARTICLE
000125525 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000125525 3367_ $$00$$2EndNote$$aJournal Article
000125525 520__ $$aCytogenetic aberrations detected by interphase fluorescence in situ hybridization (iFISH) of plasma cells are routinely evaluated as prognostic markers in multiple myeloma. This long-term follow-up study aimed to assess the prognosis of systemic light chain amyloidosis (AL) patients treated with high-dose melphalan (HDM) chemotherapy and autologous stem cell transplantation, depending on iFISH results. Therefore, we analyzed a consecutive cohort of 123 AL patients recruited from 2003 to 2014. HDM was safe, with only 1 of 123 patients dying as a result of treatment-related mortality, and effective, with a complete remission (CR) rate of 34%. Translocation t(11;14) as the most prevalent aberration (59%) led to an improved CR rate after high-dose therapy (41.2% vs 20.0%; P = .02), translating into a prolonged hematologic event-free survival (hemEFS; median, 46.1 vs 28.1 months; P = .05) and a trend for better overall survival (median, not reached vs 93.7 months; P = .07). In multivariate analysis, t(11;14) was confirmed as a favorable prognostic factor regarding hemEFS along with lower values for the difference between involved and uninvolved free light chains. Conversely, deletion 13q14, gain of 1q21, and hyperdiploidy had no significant prognostic impact. The high-risk cytogenetic aberrations t(4;14), t(14;16), and del(17p13) conferred an unfavorable prognosis, although statistical significance was reached only for univariate CR analysis in this small group of 9 patients. Thus, t(11;14) positivity in HDM-treated AL patients conferred superior CR rates and hemEFS. In view of the reduced response of t(11;14) to bortezomib, this highlights the impact of therapy on the prognostic role of cytogenetic aberrations.
000125525 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000125525 588__ $$aDataset connected to CrossRef, PubMed,
000125525 650_7 $$2NLM Chemicals$$aImmunoglobulin Light Chains
000125525 650_7 $$0Q41OR9510P$$2NLM Chemicals$$aMelphalan
000125525 7001_ $$aHegenbart, Ute$$b1
000125525 7001_ $$0P:(DE-He78)a9f6104e5c2c26345dcb242e6bdcb2b2$$aKunz, Christina$$b2$$udkfz
000125525 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b3$$udkfz
000125525 7001_ $$aKimmich, Christoph$$b4
000125525 7001_ $$aSeckinger, Anja$$b5
000125525 7001_ $$aHose, Dirk$$b6
000125525 7001_ $$aGoldschmidt, Hartmut$$b7
000125525 7001_ $$aGranzow, Martin$$b8
000125525 7001_ $$aDreger, Peter$$b9
000125525 7001_ $$aHo, Anthony D$$b10
000125525 7001_ $$aJauch, Anna$$b11
000125525 7001_ $$aSchönland, Stefan O$$b12
000125525 773__ $$0PERI:(DE-600)1468538-3$$a10.1182/blood-2015-10-676361$$gVol. 128, no. 4, p. 594 - 602$$n4$$p594 - 602$$tBlood$$v128$$x1528-0020$$y2016
000125525 909CO $$ooai:inrepo02.dkfz.de:125525$$pVDB
000125525 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c741dc7f974390ad4310349f29aac40b$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000125525 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a9f6104e5c2c26345dcb242e6bdcb2b2$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000125525 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000125525 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000125525 9141_ $$y2016
000125525 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBLOOD : 2015
000125525 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000125525 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000125525 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000125525 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000125525 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000125525 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000125525 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000125525 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000125525 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000125525 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000125525 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000125525 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000125525 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bBLOOD : 2015
000125525 9201_ $$0I:(DE-He78)G330-20160331$$kG330$$lKKE Molekulare Hämatologie/Onkologie$$x0
000125525 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x1
000125525 980__ $$ajournal
000125525 980__ $$aVDB
000125525 980__ $$aI:(DE-He78)G330-20160331
000125525 980__ $$aI:(DE-He78)C060-20160331
000125525 980__ $$aUNRESTRICTED